Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 28

1.

Ki-67 Expression as a Factor Predicting Recurrence of Ductal Carcinoma In Situ of the Breast: A Systematic Review and Meta-Analysis.

Poulakaki N, Makris GM, Papanota AM, Marineli F, Marinelis A, Battista MJ, Boehm D, Psyrri A, Sergentanis TN.

Clin Breast Cancer. 2018 Apr;18(2):157-167.e6. doi: 10.1016/j.clbc.2017.12.007. Epub 2017 Dec 16.

PMID:
29325859
2.

Hormonal receptor status, Ki-67 and HER2 expression: Prognostic value in the recurrence of ductal carcinoma in situ of the breast?

Poulakaki N, Makris GM, Battista MJ, Böhm D, Petraki K, Bafaloukos D, Sergentanis TN, Siristatidis C, Chrelias C, Papantoniou N.

Breast. 2016 Feb;25:57-61. doi: 10.1016/j.breast.2015.10.007. Epub 2015 Nov 21.

PMID:
26612082
3.

Prognostic influence of cyclooxygenase-2 protein and mRNA expression in node-negative breast cancer patients.

Sicking I, Rommens K, Battista MJ, Böhm D, Gebhard S, Lebrecht A, Cotarelo C, Hoffmann G, Hengstler JG, Schmidt M.

BMC Cancer. 2014 Dec 15;14:952. doi: 10.1186/1471-2407-14-952.

4.

Nationwide analysis on surgical staging procedures and systemic treatment for patients with endometrial cancer in Germany.

Battista MJ, Steiner E, Rieks N, Steetskamp J, Seeger A, Sicking I, Böhm D, Schmidt M, Koelbl H.

Int J Gynecol Cancer. 2013 Jan;23(1):105-12. doi: 10.1097/IGC.0b013e3182781a6c.

PMID:
23262520
5.

Expression of aurora kinase A is associated with metastasis-free survival in node-negative breast cancer patients.

Siggelkow W, Boehm D, Gebhard S, Battista M, Sicking I, Lebrecht A, Solbach C, Hellwig B, Rahnenführer J, Koelbl H, Gehrmann M, Marchan R, Cadenas C, Hengstler JG, Schmidt M.

BMC Cancer. 2012 Nov 27;12:562. doi: 10.1186/1471-2407-12-562.

6.

Immunoglobulin kappa C predicts overall survival in node-negative breast cancer.

Chen Z, Gerhold-Ay A, Gebhard S, Boehm D, Solbach C, Lebrecht A, Battista M, Sicking I, Cotarelo C, Cadenas C, Marchan R, Stewart JD, Gehrmann M, Koelbl H, Hengstler JG, Schmidt M.

PLoS One. 2012;7(9):e44741. doi: 10.1371/journal.pone.0044741. Epub 2012 Sep 28.

7.

Skin-reducing Mastectomy with Primary Implant Reconstruction.

Siggelkow W, Lübbe K, Gade J, Kölbl H, Schmidt M, Böhm D.

Geburtshilfe Frauenheilkd. 2012 Jul;72(7):616-621.

8.

Comparison of tear protein levels in breast cancer patients and healthy controls using a de novo proteomic approach.

Böhm D, Keller K, Pieter J, Boehm N, Wolters D, Siggelkow W, Lebrecht A, Schmidt M, Kölbl H, Pfeiffer N, Grus FH.

Oncol Rep. 2012 Aug;28(2):429-38. doi: 10.3892/or.2012.1849. Epub 2012 Jun 1.

9.

A comprehensive analysis of human gene expression profiles identifies stromal immunoglobulin κ C as a compatible prognostic marker in human solid tumors.

Schmidt M, Hellwig B, Hammad S, Othman A, Lohr M, Chen Z, Boehm D, Gebhard S, Petry I, Lebrecht A, Cadenas C, Marchan R, Stewart JD, Solbach C, Holmberg L, Edlund K, Kultima HG, Rody A, Berglund A, Lambe M, Isaksson A, Botling J, Karn T, Müller V, Gerhold-Ay A, Cotarelo C, Sebastian M, Kronenwett R, Bojar H, Lehr HA, Sahin U, Koelbl H, Gehrmann M, Micke P, Rahnenführer J, Hengstler JG.

Clin Cancer Res. 2012 May 1;18(9):2695-703. doi: 10.1158/1078-0432.CCR-11-2210. Epub 2012 Feb 20.

10.

p53 is correlated with low BMI negative progesterone receptor status and recurring disease in patients with endometrial cancer.

Seeger A, Kölbl H, Petry IB, Gebhard S, Battista MJ, Böhm D, Steiner E.

Gynecol Oncol. 2012 Apr;125(1):200-7. doi: 10.1016/j.ygyno.2011.12.443. Epub 2011 Dec 28.

PMID:
22210468
11.

Prospective randomized comparison of conventional instruments and the Harmonic Focus(®) device in breast-conserving therapy for primary breast cancer.

Böhm D, Kubitza A, Lebrecht A, Schmidt M, Gerhold-Ay A, Battista M, Stewen K, Solbach C, Kölbl H.

Eur J Surg Oncol. 2012 Feb;38(2):118-24. doi: 10.1016/j.ejso.2011.11.003. Epub 2011 Dec 5.

PMID:
22152942
12.

Antibody microarray analysis of the serum proteome in primary breast cancer patients.

Böhm D, Keller K, Boehm N, Lebrecht A, Schmidt M, Kölbl H, Grus FH.

Cancer Biol Ther. 2011 Nov 1;12(9):772-9. doi: 10.4161/cbt.12.9.17675. Epub 2011 Nov 1.

PMID:
21885915
13.

Serum proteome profiling of primary breast cancer indicates a specific biomarker profile.

Böhm D, Keller K, Wehrwein N, Lebrecht A, Schmidt M, Kölbl H, Grus FH.

Oncol Rep. 2011 Nov;26(5):1051-6. doi: 10.3892/or.2011.1420. Epub 2011 Aug 11.

PMID:
21837365
14.

Primary Leiomyosarcoma of the Male Breast.

Boehm D, Keller K, Schmidt M, Cotarelo C, Kern A, Lebrecht A, Koelbl H.

World J Oncol. 2010 Oct;1(5):210-212. doi: 10.4021/wjon238w. Epub 2010 Nov 2.

15.

Ep-CAM RNA expression predicts metastasis-free survival in three cohorts of untreated node-negative breast cancer.

Schmidt M, Petry IB, Böhm D, Lebrecht A, von Törne C, Gebhard S, Gerhold-Ay A, Cotarelo C, Battista M, Schormann W, Freis E, Selinski S, Ickstadt K, Rahnenführer J, Sebastian M, Schuler M, Koelbl H, Gehrmann M, Hengstler JG.

Breast Cancer Res Treat. 2011 Feb;125(3):637-46. doi: 10.1007/s10549-010-0856-5. Epub 2010 Mar 30.

PMID:
20352488
16.

A new algorithm for improving fetal weight estimation from ultrasound data at term.

Siggelkow W, Schmidt M, Skala C, Boehm D, von Forstner S, Koelbl H, Tresch A.

Arch Gynecol Obstet. 2011 Mar;283(3):469-74. doi: 10.1007/s00404-010-1390-8. Epub 2010 Feb 20.

17.

Quality of life and adjuvant tamoxifen treatment in breast cancer patients.

Boehm DU, Lebrecht A, Eckhardt T, Albrich S, Schmidt M, Siggelkow W, Kandelhardt E, Koelbl H.

Eur J Cancer Care (Engl). 2009 Sep;18(5):500-6. doi: 10.1111/j.1365-2354.2008.01015.x. Epub 2009 May 21.

PMID:
19490009
18.

Diagnosis of breast cancer by tear proteomic pattern.

Lebrecht A, Boehm D, Schmidt M, Koelbl H, Schwirz RL, Grus FH.

Cancer Genomics Proteomics. 2009 May-Jun;6(3):177-82.

19.

Surface-enhanced Laser Desorption/Ionisation Time-of-flight Mass Spectrometry to Detect Breast Cancer Markers in Tears and Serum.

Lebrecht A, Boehm D, Schmidt M, Koelbl H, Grus FH.

Cancer Genomics Proteomics. 2009 Mar-Apr;6(2):75-83.

20.

Long-term outcome prediction by clinicopathological risk classification algorithms in node-negative breast cancer--comparison between Adjuvant!, St Gallen, and a novel risk algorithm used in the prospective randomized Node-Negative-Breast Cancer-3 (NNBC-3) trial.

Schmidt M, Victor A, Bratzel D, Boehm D, Cotarelo C, Lebrecht A, Siggelkow W, Hengstler JG, Elsässer A, Gehrmann M, Lehr HA, Koelbl H, von Minckwitz G, Harbeck N, Thomssen C.

Ann Oncol. 2009 Feb;20(2):258-64. doi: 10.1093/annonc/mdn590. Epub 2008 Sep 29.

PMID:
18824499

Supplemental Content

Loading ...
Support Center